What Sareum Holdings PLC does

Sareum Holdings PLC is a clinical-stage small molecule drug discovery company headquartered in Pampisford, Cambridge, UK, listed on the AIM market of the London Stock Exchange (ticker: SAR) and founded in 2003. The company focuses on next-generation kinase inhibitors targeting the TYK2/JAK1 cell signalling pathway for autoimmune diseases and the Chk1 checkpoint kinase for cancer, using its proprietary SKIL (Sareum Kinase Inhibitor Library) discovery platform. Its pipeline comprises three assets: SDC-1801, a dual TYK2/JAK1 inhibitor for psoriasis and other autoimmune diseases that completed a Phase 1 trial in 95 healthy participants; SDC-1802, a preclinical TYK2/JAK1 inhibitor for cancer immunotherapy in indications such as T-ALL and B-cell lymphoma; and SRA737, an oral selective Chk1 inhibitor that completed two Phase 1/2 trials under former licensee Sierra Oncology (now GSK), with rights re-acquired by Sareum in March 2025. A new TYK2/JAK1 CNS programme targeting neuro-inflammatory conditions including multiple sclerosis and Parkinson's disease is being advanced via an August 2025 AI collaboration with Receptor.AI.

The company operates an asset-light, licensing-focused business model. Sareum maintains a lean in-house team (1-10 employees) and engages fee-for-service research providers to run laboratory-based R&D, advancing programmes to late preclinical or early clinical stages before seeking to licence them to international pharmaceutical and biotechnology partners. It pursues multiple programmes in parallel and has a broad granted patent estate covering TYK2 and Chk1 inhibitor composition-of-matter and crystalline forms across the US, EP, JP, and CN. Revenue to date has been non-commercial in nature, comprising an October 2024 £2.364 million share subscription, a £1 million Australian R&D tax credit, and a 2020 £174,000 UKRI grant; the company does not yet generate licensing or product revenue and has no consumer-facing pricing model.

Sareum's commercial go-to-market is exclusively B2B and channeled through direct business development outreach, industry partnering conferences (notably the BIO International Convention, where it is scheduled to participate in June 2026), and engagement with AIM-market investors via RNS announcements, broker research (Hybridan LLP), and third-party equity research (Edison Group). Customer segments are defined by therapeutic indication rather than company size: pharmaceutical partners seeking differentiated kinase inhibitors for autoimmune disease, oncology partners interested in DNA damage repair and cancer immunotherapy mechanisms, and (more recently) neuroscience-focused partners requiring CNS-penetrant molecules for neuro-inflammation. The former licence relationship with Sierra Oncology, whose 2022 acquisition by GSK materially altered the asset's commercial path, illustrates both the structural concentration risk and the deal-by-deal nature of the licensing model.

Name

Sareum Holdings PLC

Legal name

Sareum Holdings PLC

Website

https://sareum.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

Sareum Holdings PLC is a UK clinical-stage biotech developing next-generation TYK2/JAK1 and Chk1 small molecule kinase inhibitors for autoimmune diseases, cancer, and neuro-inflammation, with three pipeline assets (SDC-1801, SDC-1802, SRA737) and a licensing-focused business model targeting global pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (kinase inhibitor drug discovery)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Kinase inhibitor discovery
• Small molecule therapeutics
• Autoimmune disease drugs
• Oncology drug development
• Pharmaceutical licensing

Headquarters

HQ city

Pampisford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Revenue: The company's primary strategy is to develop programmes to late preclinical or early clinical stages before licensing to pharmaceutical partners, generating revenues through licensing agreements and milestone payments. The business model focuses on building a rich pipeline of clinical-stage medicines with licence deals that produce self-sustaining revenues.
2. R&D Tax Credits: Sareum received a £1 million R&D tax credit from Australia to support development of its pharmaceutical programmes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Sareum Holdings PLC is a clinical-stage biopharmaceutical company that discovers and develops next-generation small molecule kinase inhibitors for autoimmune diseases and cancer. Its pipeline comprises SDC-1801 (TYK2/JAK1 inhibitor for autoimmune disease, Phase 1 completed), SDC-1802 (TYK2/JAK1 inhibitor for cancer immunotherapy, preclinical) and SRA737 (Chk1 inhibitor for cancer, Phase 1/2 completed, licence re-acquired in March 2025). The company develops programmes to late preclinical or early clinical stages and then out-licences them to pharmaceutical and biotechnology partners.

Product overview

Sareum Holdings PLC is a clinical-stage small molecule pharmaceutical company developing next-generation kinase inhibitors to treat autoimmune diseases and cancer. The company's pipeline is primarily focused on the TYK2/JAK1 kinase cell signalling family. The core product portfolio consists of three drug candidates: SDC-1801 (TYK2/JAK1 inhibitor for autoimmune diseases, primarily psoriasis, in Phase 1 clinical development), SDC-1802 (TYK2/JAK1 inhibitor for cancer immunotherapy, in preclinical development), and SRA737 (licensed CHK1 inhibitor for cancer, completed Phase 2 trials). The company operates a licensing-focused business model, developing programmes to late preclinical or early clinical stages before partnering with pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• SDC-1801 A potent and selective dual TYK2/JAK1 inhibitor being developed as a treatment for autoimmune diseases, with a particular focus on psoriasis. Demonstrates high selectivity for TYK2 and JAK1 over JAK2 and JAK3, compelling activity in disease models of psoriasis and rheumatoid arthritis, once-daily oral dosing potential and a favourable early safety profile. Phase 1 has been completed. Intended to be out-licensed to pharmaceutical partners at preclinical or early clinical stages.
• SDC-1802

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Receptor.AIcoreTechnology or Integration · 1 August 2025AI collaboration for neuroscience drug discovery focused on accelerating the discovery and optimisation of blood-brain barrier-penetrant, isoform-selective TYK2/JAK1 inhibitors for neuro-inflammatory indications including multiple sclerosis and Parkinson's disease. Collaboration applies virtual screening, generative chemistry, and predictive modelling. Sareum retains full ownership of all IP and compounds arising from the collaboration. First batch of compounds already designed, synthesised and entered early-stage testing.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Redx Pharma: UK-listed (AIM) clinical-stage small molecule drug discovery company developing targeted therapies in oncology and fibrotic disease, with a similar asset-light, licensing-oriented business model and lean team structure.
• Evgen Pharma: UK-listed (AIM) clinical-stage biotech developing small molecule therapeutics, similarly structured with a small team, outsourcing to CROs, and aiming to license assets to larger pharma partners.
• Nimbus Therapeutics: Private US-based small molecule drug discovery company whose TYK2 allosteric inhibitor (NDI-034858 / deucravacitinib) was licensed to Bristol Myers Squibb, making it a directly comparable TYK2-focused asset developer with a licensing business model.

Emerging players

• Karus Therapeutics: UK-based small molecule oncology biotech developing kinase and epigenetic inhibitors; comparable in focus on kinase-targeted small molecules and stage of development, though targeting different kinase programmes.

Broad incumbents

• Bicycle Therapeutics: Cambridge UK-based clinical-stage biotech with a broader platform of bicyclic peptide therapeutics and a licensing/partnering strategy, sharing Sareum's Cambridge ecosystem, AIM/Nasdaq listing profile and pharma-partnering orientation.
• Bristol Myers Squibb: Large pharma company whose TYK2 inhibitor deucravacitinib (Sotyktu) is approved in psoriasis; sets the benchmark for what a 'best-in-class' TYK2 programme must beat and is the most likely licensing counterparty for Sareum.
• Pfizer: Major pharma with an extensive JAK franchise (e.g., tofacitinib, abrocitinib) and active TYK2 programme; a primary potential licensing partner for Sareum and a benchmark competitor in autoimmune kinase space.

Regional players

• PureTech Health: UK-listed clinical-stage biotech that develops and partners therapeutic programmes; comparable in size, capital-markets profile, and focus on early-stage licensing of differentiated small molecule and biologic assets.
• Celon Pharma: Poland-based clinical-stage specialty pharma developing kinase inhibitors and other targeted small molecules; comparable in therapeutic area (kinase inhibition) and stage, though primarily serving European rather than UK markets.

Others

• Receptor.AI: AI-driven drug discovery platform that is Sareum's named partner for the CNS TYK2/JAK1 programme; included as an ecosystem/technology peer because it is directly enabling Sareum's pipeline expansion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/sareumplc
• LinkedInlinkedin.com/company/121132

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sareum Holdings PLC